If you have been reading about lyophilized peptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-05-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Measuring the effect of a growth hormone-releasing hormone analogue requires markers that reflect pituitary output rather than the peptide itself. The two most frequently used are growth hormone and insulin-like growth factor 1. Growth hormone fluctuates sharply across the day and responds to sleep, stress, and meals, so isolated readings can be difficult to interpret. Insulin-like growth factor 1 changes more slowly and is often treated as the more stable integrated marker of axis activity.
Because growth hormone is released in pulses, single measurements can misrepresent overall secretion. Investigators sometimes use repeated sampling or overnight profiles to capture the pattern rather than a single value. Provocative testing, in which a stimulus is given and the response is tracked over time, offers another way to characterize the axis. Each approach carries trade-offs between sensitivity, burden on the participant, and the influence of non-target variables.
Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | GHRH analog family |
| Residue count | 44 amino acids | Matches human GHRH(1-44) backbone |
| N-terminal group | trans-3-hexenoyl | Main structural difference from native hormone |
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility class | Freely soluble in water | Peptide character; less soluble in organic solvents |
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
It was estimated in 2017 that nearly one in three persons globally had at least one form of malnutrition: wasting, stunting, vitamin or mineral deficiency, overweight, obesity, or diet-related noncommunicable diseases. Undernutrition is more common in developing countries. Stunting is more prevalent in urban slums than in rural areas. Studies on malnutrition have the population categorised into different groups including infants, under-five children, children, adolescents, pregnant women, adults and the elderly population. The use of different growth references in different studies leads to variances in the undernutrition prevalence reported in different studies. Some of the growth references used in studies include the National Center for Health Statistics (NCHS) growth charts, WHO reference 2007, Centers for Disease Control and Prevention (CDC) growth charts, National Health and Nutrition Examination Survey (NHANES), WHO reference 1995, Obesity Task Force (IOTF) criteria and Indian Academy of Pediatrics (IAP) growth charts. In 2023, an estimated 28.9 percent of the global population – 2.33 billion people – were moderately or severely food insecure.
=== EC 1.16.1 With NAD+ or NADP+ as acceptor === EC 1.16.1.1: mercury(II) reductase EC 1.16.1.2: diferric-transferrin reductase EC 1.16.1.3: deleted since no specific enzyme catalysing this activity has been identified EC 1.16.1.4: cob(II)alamin reductase EC 1.16.1.5: deleted since the enzyme the entry was based on was later shown to be EC 1.2.1.51, pyruvate dehydrogenase (NADP+). EC 1.16.1.6: cyanocobalamin reductase (cyanide-eliminating) EC 1.16.1.7: ferric-chelate reductase EC 1.16.1.8: [methionine synthase] reductase EC 1.16.1.9: ferric-chelate reductase (NADPH) EC 1.16.1.10: ferric-chelate reductase [NAD(P)H]
Alonso de Ojeda (who had sailed with Columbus) reached the Guajira Peninsula in 1499. Spanish explorers, led by Rodrigo de Bastidas, made the first exploration of the Caribbean coast in 1500. Christopher Columbus navigated near the Caribbean in 1502. In 1508, Vasco Núñez de Balboa accompanied an expedition to the territory through the region of Gulf of Urabá and they founded the town of Santa María la Antigua del Darién in 1510, the first stable settlement on the continent. Santa Marta was founded in 1525, and Cartagena in 1533. Spanish conquistador Gonzalo Jiménez de Quesada led an expedition to the interior in April 1536, and christened the districts through which he passed "New Kingdom of Granada". In August 1538, he provisionally founded its capital near the Muisca cacicazgo of Muyquytá, and named it "Santa Fe". The name soon acquired a suffix and was called Santa Fe de Bogotá. Two other notable journeys by early conquistadors to the interior took place in the same period. Sebastián de Belalcázar, conqueror of Quito, traveled north and founded Cali, in 1536, and Popayán, in 1537; from 1536 to 1539, German conquistador Nikolaus Federmann crossed the Llanos Orientales and went over the Cordillera Oriental in a search for El Dorado, the "city of gold". The legend and the gold would play a pivotal role in luring the Spanish and other Europeans to New Granada during the 16th and 17th centuries. The conquistadors made frequent alliances with the enemies of different indigenous communities.
=== August === 2 August – The BBC reports that Labour has shelved £1.3bn of funding promised by the Conservatives for tech and artificial intelligence (AI) projects, including an exascale supercomputer at Edinburgh University. 6 August – The UK government begins the process of drawing up legislation to abolish the Strikes (Minimum Service Levels) Act 2023, which required striking workers such as teachers, firefighters and railway staff to provide a minimum level of service. The Senedd is recalled to choose a new First Minister of Wales, with Eluned Morgan nominated to become the first woman to hold the post. 7 August – Ofcom have received more than 8,200 complaints about two interviews during the 5 August edition of Good Morning Britain – the first involving presenter Ed Balls who spoke to his wife, Home Secretary Yvette Cooper, and the second involving an interview Balls and Kate Garraway did with Labour MP Zarah Sultana. Mark Drakeford, Wales's former first minister, returns to government after he is appointed health secretary by Eluned Morgan. 8 August – The Northern Ireland Assembly is recalled to discuss the 2024 United Kingdom riots. Nominations open for the 2024 Scottish Conservatives leadership election. Ricky Jones, a Labour councillor in Dartford, is suspended by his party and arrested over comments made at an anti-racism rally the previous day in which he suggested far-right protestors who took part in the 2024 UK riots should have their throats cut.
Sources: en.wikipedia.org
Another use of depleted uranium is in kinetic energy penetrators, anti-armor rounds such as the 120 mm sabot rounds fired from the British Challenger 1 and Challenger 2, as well as the American M1A1 and M1A2 Abrams. Kinetic energy penetrator rounds consist of a long, relatively thin penetrator surrounded by a discarding sabot. Staballoys are metal alloys of depleted uranium with a very small proportion of other metals, usually titanium or molybdenum. One formulation has a composition of 99.25% by mass of depleted uranium and 0.75% by mass of titanium. Staballoys are approximately 1.67 times as dense as lead and are designed for use in kinetic energy penetrator armor-piercing ammunition. The US Army uses DU in an alloy with around 3.5% titanium. Depleted uranium is favored for the penetrator because it is self-sharpening and flammable. On impact with a hard target, such as an armored vehicle, the tip of the projectile will be "mushroomed", while the back of the projectile is still a rigid solid. This leads to adiabatic shearing, and together with the spin of the projectile results in a shedding of the mushroomed plastic phase in such a way that it forms a new sharp tip. This shedding of the mushroomed tip improves penetration properties compared to the complete dispersal that takes place with tungsten penetrators, therefore DU penetrators are 20% more effective than tungsten rounds. The impact and subsequent release of heat energy causes it to ignite when in contact with oxygen.
Because lithium-ion batteries can have a variety of positive and negative electrode materials, the energy density and voltage vary accordingly. The open-circuit voltage is higher than in aqueous batteries (such as lead–acid, nickel–metal hydride and nickel–cadmium). Internal resistance increases with both cycling and age, although this depends strongly on the voltage and temperature the batteries are stored at. Rising internal resistance causes the voltage at the terminals to drop under load, which reduces the maximum current draw. Eventually, increasing resistance will leave the battery in a state such that it can no longer support the normal discharge currents requested of it without unacceptable voltage drop or overheating. Batteries with a lithium iron phosphate positive and graphite negative electrodes have a nominal open-circuit voltage of 3.2 V and a typical charging voltage of 3.6 V. Lithium nickel manganese cobalt (NMC) oxide positives with graphite negatives have a 3.7 V nominal voltage with a 4.2 V maximum while charging. The charging procedure is performed at constant voltage with current-limiting circuitry (i.e., charging with constant current until a voltage of 4.2 V is reached in the cell and continuing with a constant voltage applied until the current drops close to zero). Typically, the charge is terminated at 3% of the initial charge current. In the past, lithium-ion batteries could not be fast-charged and needed at least two hours to fully charge. Current-generation cells can be fully charged in 45 minutes or less.
Sack–Barabas syndrome (SBS) is an older name for vascular Ehlers–Danlos syndrome (vEDS). It is a medical condition, a subset of Ehlers–Danlos syndrome which especially affects the body's vascular system, including blood vessels and organs, and makes them prone to rupture.
== History == The use of cold for pain relief and as an anti-inflammatory has been known since the time of Hippocrates (460–377 BC). Since then there have been numerous accounts of ice used for pain relief, including from the Ancient Egyptians and Avicenna of Persia (982–1070 AD). In 1812, Napoleon's surgeon general noted that half-frozen soldiers from the Moscow battle were able to tolerate amputations with reduced pain. In 1851, ice and salt mixtures were promoted by Arnott for the treatment of nerve pain. Campbell White, in 1899, was the first to use refrigerants medically, and Allington, in 1950, was the first to use liquid nitrogen for medical treatments. In 1961, Cooper et al. created an early cryoprobe that reached −190 °C using liquid nitrogen. Shortly thereafter, in 1967, an ophthalmic surgeon named Amoils used carbon dioxide and nitrous oxide to create a cryoprobe that reached −70 °C.
The Samar cobra (Naja samarensis) is a highly venomous species of spitting cobra that is found in the southern islands of the Philippines. Although it is a spitting cobra, this species only rarely spits its venom. It is considered to be an extremely aggressive snake that strikes with little provocation. The venom of this species is not well studied, but is known to be an extremely potent postsynaptic neurotoxin that also contains cytotoxic agents. According to Ernst & Zug et al. the murine SC LD50 value is 0.21 mg/kg, making it one of the most venomous true cobra species (genus Naja) in the world. Severe envenomation is likely in case of a bite and envenomation rate is high. The untreated mortality rate is not known, but is thought to be high (~60%). Envenomation results in marked local effects such as pain, severe swelling, bruising, blistering, and necrosis. Other effects include headache, nausea, vomiting, abdominal pain, diarrhea, dizziness, collapse or convulsions. There may also be moderate to severe flaccid paralysis and kidney damage. Cardiotoxicity is possible, but rare.
Sources: en.wikipedia.org
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.
It blocks the amino-terminal degradation step that limits native GHRH. The addition extends how long the peptide survives in plasma without removing its ability to activate the receptor.
The chain contains 44 amino acid residues. It matches the human GHRH(1-44) sequence apart from the amino-terminal modification.
It varies slowly and reflects cumulative axis activity rather than momentary secretion. Growth hormone is released in pulses affected by sleep, stress, and meals, making single readings hard to interpret. The slower marker gives a more stable picture across a study period.